| (Values in U.S. Thousands) | Mar, 2019 | Dec, 2018 | Sep, 2018 | Jun, 2018 | Mar, 2018 |
| Sales | 7,630 | 16,360 | 18,350 | 23,470 | 23,910 |
| Sales Growth | -53.36% | -10.84% | -21.82% | -1.84% | -24.05% |
| Net Income | -123,840 | -46,290 | -30,490 | -27,350 | -20,370 |
| Net Income Growth | -167.53% | -51.82% | -11.48% | -34.27% | +56.65% |
Insys Therapeutics Inc
(INSY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. It is engaged in the development and commercialization of pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray and Dronabinol SG capsule. Insys Therapeutics, Inc. is based in Phoenix, Arizona.